Benchmark Capital upgrades BioMarin (Nasdaq: BMRN) from Hold to Buy. Price target $22

Benchmark analyst says, "BioMarin announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE